乳腺癌患者血清NR3C2、PGRMC1、CA153水平及临床意义

Serum levels of NR3C2, PGRMC1, and CA153 in breast cancer patients and their clinical significance

摘要

目的 探讨乳腺癌（BC）患者血清核受体亚家族C组成员2（NR3C2）、孕激素受体膜组分1（PGRMC1）、糖类抗原153（CA153）水平对术后复发转移的预测价值。方法 选取2021年1月—2023年1月于南阳市中心医院接受BC改良根治术的102例患者作为研究对象,依据术后1年是否发生复发转移,将其分为发生组38例、未发生组64例。采用ELISA法检测血清NR3C2、PGRMC1水平,免疫化学发光法检测血清CA153水平。ROC分析血清NR3C2、PGRMC1、CA153对术后复发转移的预测价值。结果 发生组术后血清NR3C2水平低于未发生组,PGRMC1、CA153水平高于未发生组（P<0.05）;偏相关性分析显示,NR3C2与术后复发转移呈负相关,PGRMC1、CA153与术后复发转移呈正相关（P<0.05）;术后2个月血清NR3C2、PGRMC1、CA153单项及联合预测术后1年复发转移的AUC值分别为0.771、0.775、0.825、0.909,且联合预测的AUC值大于单项指标预测（P<0.05）。结论 血清NR3C2、PGRMC1、CA153对BC患者术后复发转移具有一定预测价值,且联合检测可提高预测效能。

Abstract

Objective To explore the predictive value of serum levels of nuclear receptor subfamily C member 2 (NR3C2), progesterone receptor membrane component 1 (PGRMC1), and carbohydrate antigen 153 (CA153) in predicting postoperative recurrence and metastasis in breast cancer patients. Methods A retrospective study was conducted on 102 breast cancer patients who underwent modified radical mastectomy at Nanyang Central Hospitall from January 2021 to January 2023. Patients were divided into two groups based on whether they experienced recurrence or metastasis one year after surgery: the occurrence group (38 cases) and the non-occurrence group (64 cases). Serum levels of NR3C2 and PGRMC1 were detected using ELISA, and serum CA153 levels were detected using immunochemical luminescence. The predictive value of serum NR3C2, PGRMC1, and CA153 for postoperative recurrent metastasis was analyzed using ROC. Results The postoperative serum levels of NR3C2 in the occurrence group were lower than those in the non-occurrence group, while the levels of PGRMC1 and CA153 were higher (P<0.05). Partial correlation analysis revealed that NR3C2 was negatively correlated with postoperative recurrence and metastasis, whereas PGRMC1 and CA153 were positively correlated (P<0.05). The AUC values for predicting postoperative 1-year recurrence and metastasis using serum levels of NR3C2, PGRMC1, and CA153, either individually or in combination, were 0.771, 0.775, 0.825, and 0.909, respectively, 2 months post-surgery. Notably, the AUC value for combined prediction was higher than that for individual indicators (P<0.05). Conclusion Serum NR3C2, PGRMC1, and CA153 have certain predictive value for postoperative recurrence and metastasis in breast cancer patients, and combined detection can improve the predictive efficacy.

关键词

乳腺癌 / 核受体亚家族C组成员2 / 孕激素受体膜组分1 / 糖类抗原153

Key words

breast cancer / nuclear receptor subfamily C group member 2 / progesterone receptor membrane component 1 / carbohydrate antigen 153

[1] 刘贺,张磊,曹恒,等. 术前CA125、OPN、CXCL8、NLR联合检测对乳腺癌改良根治术患者术后复发转移风险的评估价值[J]. 现代生物医学进展,2022,22(9):1718-1723.
[2] Liu H, Lei WQ, Li ZG, et al.NR3C2 inhibits the proliferation of colorectal cancer via regulating glucose metabolism and phosphorylating AMPK[J]. J Cell Mol Med, 2023, 27(8): 1069-1082.
[3] Zhao Y, Ruan X, Cheng J, et al.PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis[J]. Climacteric, 2023, 26(2): 135-142.
[4] 刘瑞杰,程树杰,魏淑强,等. 乳腺癌血清TPS、CA153、VEGF水平及意义[J]. 河北医药,2021,43(6):911-914.
[5] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志,2021,31(10):954-1040.
[6] 李慧芳,地力木拉提·艾斯木吐拉,郭晨明,等. 乳腺癌改良根治术患者术后复发转移的危险因素及血清CA125、COX-2、sTNFR-P55的预测价值研究[J]. 现代生物医学进展,2023,23(2):384-389.
[7] 郭檬檬,姚昶. 血清外泌体miR-155、miR-222表达对乳腺癌术后复发转移的预测价值[J]. 安徽医药,2022,26(10):1997-2000.
[8] Li J, Xu Z.NR3C2 suppresses the proliferation, migration, invasion and angiogenesis of colon cancer cells by inhibiting the AKT/ERK signaling pathway[J]. Mol Med Rep, 2022, 25(4): 133-143.
[9] 张凌捷,葛睿,程爱群,等. 乳腺癌患者血清NR3C2和DNMT3A表达水平及其诊断价值研究[J]. 现代检验医学杂志,2023,38(6):120-124.
[10] Sun YY, Gao HC, Guo P, et al.Identification of NR3C2 as a functional diagnostic and prognostic biomarker and potential therapeutic target in non-small cell lung cancer[J]. Cancer Innov, 2024, 3(4): e122-e132.
[11] Peng Y, Xi X, Li JT, et al.miR-301b and NR3C2 co-regulate cells malignant properties and have the potential to be independent prognostic factors in breast cancer[J]. J Biochem Mol Toxicol, 2021, 35(2): e22650-e22660.
[12] 吴菊梅,姚利桦,金小宁,等. 血清表皮生长因子受体和全血孕激素受体膜成分1联合检测在乳腺癌早期诊断中的价值[J]. 中国老年学杂志,2020,40(14):2964-2967.
[13] 张邢松,吴雅珣,贾美群. PGRMC1在宫颈癌组织中的表达及对细胞增殖的影响[J]. 现代肿瘤医学,2021,29(16):2876-2879.
[14] 王真真,邓青,付云. 血清TFF1、SLPI、PGRMC1水平对乳腺癌的诊断价值及与病理因素的相关性分析[J]. 淮海医药,2023,41(6):571-575.
[15] 赵越,阮祥燕,程姣姣,等. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报,2022,43(3):350-356.
[16] 刘冲,李胜,张瑾. 血清CA153、miR-335联合检测对早期乳腺癌的诊断价值[J]. 检验医学与临床,2023,20(8):1046-1049.
[17] 许思哲,贺功建,曾黎,等. 乳腺癌根治术患者化疗前后血清CA153、CA125、TPS水平变化及对预后的影响[J]. 实用癌症杂志,2020,35(4):639-642.